UBS Group upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from "Neutral" to "Buy" on October 15, 2026. The firm also raised its price target from $660 to $978. This suggests a potential upside of over 22% from the stock's price at the time.
UBS bases its positive outlook on the long-term growth potential of Regeneron's blockbuster immunology drug, Dupixent. UBS analyst Joon Lee states the market undervalues the company's pipeline of follow-on candidates for Dupixent. These candidates could extend the drug's exclusivity and revenue generation. Lee projects Dupixent-related revenue could reach $16 billion by 2035, surpassing the current consensus estimate of $13 billion.